BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | $885.72M |
| Gross Profit (TTM) | $678.70M |
| EBITDA | $326.46M |
| Operating Margin | -2.45% |
| Return on Equity | -1925.00% |
| Return on Assets | 42.60% |
| Revenue/Share (TTM) | $4.06 |
| Book Value | $-2.18 |
| Price-to-Book | 56.59 |
| Price-to-Sales (TTM) | 2.38 |
| EV/Revenue | 3.032 |
| EV/EBITDA | 7.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $254.16M |
| Float | $220.85M |
| % Insiders | 1.15% |
| % Institutions | 100.88% |
Volatility is currently expanding